Skip to main content

Table 1 Clinicopathological data of enrolled participants (N = 47)

From: Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study

Clinicopathological Variables

Entire cohort

(N = 47)

Non-recurrence (N = 40)

Recurrence

(N = 7)

Age (Mean ± SD)

47.6 ± 12.9 years

48.6 ± 13.3 years

39.7 ± 8.2 years

Follow up (Median, IQR)

80, 33.5 months

85.5, 44.4 months

27.1, 41.4 months

Tumor type (N [%])

IDC

ILC

IMC

42 (89.3%)

2 (4.3%)

3 (6.4%)

36 (90%)

2 (5%)

2 (5%)

6 (85.7%)

0

1 (14.3%)

Breast Cancer subtype (N [%])

Hormone Receptor Positive (ER or PR)

27 (57.4%)

23 (57.5%)

4 (57.1%)

HER2-Receptor Positive

24 (51.1%)

21 (52.5%)

3 (42.9%)

Triple Negative Receptor

8 (17.0%)

7 (17.5%)

1 (14.3%)

RCB Index (N [%])

pCR

Class I

Class II

Class III

12 (25.5%)

10 (21.3%)

18 (38.3%)

7 (14.9%)

12 (30%)

9 (22.5%)

16 (40%)

3 (7.5%)

0

1 (14.3%)

2 (28.6%)

4 (57.1%)

Recurrence (N [%])

7 (14.9%)

  
  1. IQR – Interquartile range, IDC-Invasive Ductal Carcinoma, ILC- Invasive Lobular Carcinoma, IMC- Invasive Mammary Carcinoma, ER – Estrogen Receptor, PR – Progesterone Receptor, HER2 – Human Epidermal growth factor Receptor 2, RCB – Residual Cancer Burden, pCR – Pathological Complete Response